In this video, Aaron Mansfield, MD, discusses a mesothelioma clinical trial currently available across the United States and in Canada using Keytruda (pembrolizumab) with or without anetumab ravtansine in patients with pleural mesothelioma with a mesothelin expression.
Anetumab ravtansine is an antibody-drug conjugate which works against the target molecule mesothelin. Mesothelioma cancers typically display a high expression of mesothelin. (We have written about this agent in the past in this blog post.) In this study, scientists combine Keytruda (pembrolizumab) with anetumab ravtansine.
Keytruda is a checkpoint inhibitor that blocks a protein called PD-1. The PD-1 protein is present on the surface of immune cells called T-cells. Consequently, Keytruda prevents PD-1 from inhibiting the immune response, and effectively takes the brakes off the immune system thereby allowing the T-cells to recognize the cancer cells and attack them.
Watch MesoTV
MesoTV and all of its informational videos are possible with the generous support of our donors and sponsors. Importantly, during this difficult time we are able to continue serving, informing, and educating the mesothelioma community. Please take note of our Season 2 sponsors at the beginning of the video: Merck; The Gori Law Firm; Early, Lucarelli, Sweeney & Meisenkothen; and AstraZeneca.
Don’t miss any of our new videos – sign up to receive our news or subscribe to our YouTube Channel by pressing the red “Subscribe” button.
MesoTV is the Mesothelioma Applied Research Foundation’s recorded video series covering pertinent conversations impacting the mesothelioma community. You can learn more at curemeso.org/mesotv.
